CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biostem US Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biostem US Corp
13555 Automobile Blvd Ste 110
Phone: (267) 295-7814p:267 295-7814 CLEARWATER, FL  33762  United States Fax: (775) 884-9383f:775 884-9383
On 1/15/2016, the SEC revoked the registration of each class of registered securities of Biostem U.S. Corp., for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Biostem US Corp is engaged primarily in the hair transplantation business using the biostem method. During the fiscal year ended February 29, 2012 (fiscal 2012), the Company provided medical procedures indirectly, including hair transplants, through a network of medical providers, performing the medical procedures on their patients, using the Company's protocols and procedures. In addition to expanding and improving its hair treatment protocols and procedures, the Company also is working on studying, exploring and pursuing other regenerative medicine opportunities, protecting its intellectual property through trademark and patent registrations and negotiating the potential acquisition of a non-United States healthcare company in the stem cell sciences business.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
11/30/20122/29/2012YesYes---

Industries
SIC Code Description
1311 Crude petroleum and natural gas
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ScottCrutchield 49 6/10/2011 6/10/2011
Chief Executive Officer, Chief Financial Officer, Director JohnSatino 66 2/22/2013 5/13/2010
Director StephenBeck 46 1/1/2012 1/1/2012

General Information
Number of Employees: 1 (As of 2/29/2012)
Outstanding Shares: 10,313,866 (As of 7/17/2013)
Shareholders: 35
Stock Exchange: OTC
Federal Tax Id: 800324801
Fax Number: (775) 884-9383


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023